Now that we are doing well (I am speaking to longs on Regeneron), I guess the immediate questions how much has this great climb upward already been built in or will it continue to climb on the news yesterday about rheumatoid arthritis. I am thinking that it will climb more now because both Dupixent and Salumibab have great potential. Thoughts are welcome as always.
sanofi is the player.
they're in there buying stock almost every day. and e wet time they ask to increase their position management says ok. long term this stock is going much higher, and I don't mean $535.
It has a pipeline, obviously excellent discovery labs, why can't REGN become a MRK, PFE or JNJ?
Not a great earnings report to say the least but there is so much good news ahead with two potential blockbuster drugs even if Praulent continues to falter. I think it's going down big time today and maybe for awhile before going up in the way we hope and I anticipate over the next four or five months. Any thoughts are welcome.
I see a $500 in the next 6-8 months
We are having a nice day today lets hope we have good follow through next week with emphasis next Thursday morning earnings and maybe some other news about these lawsuits. Have a great weekend.
Overall I think we will see upside for REGN in the short-term. Perhaps a pullback next day or so could occur I suppose but are yall also seeing a further leg higher? Yo you should really check out awesome-STOCKS, they seem on point with their stocks.
Nice little spike in the last 15 minuets. Looks like a potential breakout ahead of earnings. Lets hope it holds and everything they say is very positive. Good luck to us all.
"Better than feared" Don't know why I click on these articles.
Anyone have thoughts about earnings? I'm debating about adding to my already very large position because I think that in two years it will be much higher but can't figure out whether we will some selling after earnings.
400+ Coming with next week's earnings. Pow!
Kramer says that Sanofi should just merge with RGEN. I agree just tare up the agreement about ownership restriction and get it done.
REGN just got bumped up from 3 (hold) to 2 (buy) from Zacks today. This is a good sign for the next few months.
REGN VERY GOOD EARNINGS BUY BUY BUY
Amgen: If you can't beat em, rob em!
Positive REGN reference in Barron's article over the weekend!
AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in Q3 2017 = 2000% POTENTIAL..UNKNOWN LOW FLOAT GEM !!!
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $85 Million Cash: $50.6 Million(cash runway into the first quarter of 2019.) Price:$3.70
Shares Out: 23 Million
Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)